Targeting the latest hallmark of cancer: another attempt at ‘magic bullet’ drugs targeting cancers’ metabolic phenotype

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Cairns R, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer11,85–95 (2011).▪▪ Detailed review of Warburg effect causes and consequences.
  Medline CASGoogle Scholar
• 2  Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell13,472–482 (2008).
  Medline CASGoogle Scholar
• 3  Allen M, Jones JL. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol.223,162–176 (2011).
  Medline CASGoogle Scholar
• 4  Tennant D, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer10,267–277 (2010).
  Medline CASGoogle Scholar
• 5  Purcell WT, Ettinger DS. Novel antifolate drugs. Curr. Oncol. Rep.5,114–125 (2003).
  MedlineGoogle Scholar
• 6  Ramos-Montoya A, Lee WN, Bassilian S et al. Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int. J. Cancer119,2733–2741 (2006).
  Medline CASGoogle Scholar
• 7  Vizan P, Alcarraz-Vizan A, Diaz-Moralli S, Solovjeva O, Frederiks WM, Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int. J. Cancer124,2789–2796 (2009).
  Medline CASGoogle Scholar
• 8  Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharm.2,1–18 (2011).
  MedlineGoogle Scholar
• 9  Cao X, Fang L, Gibbs S et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemo Pharm.59,495–505 (2007).
  Medline CASGoogle Scholar
• 10  Flaig TW, Glodé M, Gustafson D et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate70(8),848–855 (2010).
  Medline CASGoogle Scholar
• 11  Zhang W, Liu Y, Chen X, Bergmeier SC. Novel inhibitors of basal glucose transport as potential anticancer agents. Bioorg. Med. Chem. Lett.20,2191–2194 (2010).
  Medline CASGoogle Scholar
• 12  Chan DA, Sutphin PD, Nguyen P et al. Targeting GLUT1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med.3,94ra70 (2011).
  Medline CASGoogle Scholar
• 13  Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene25,4633–4646 (2006).
  Medline CASGoogle Scholar
• 14  Chen W, Guéron M. The inhibition of bovine heart hexokinase by 2-deoxy-D-glucose-6-phosphate: characterization by 31P NMR and metabolic implications. Biochimie74,867–873 (1992).
  Medline CASGoogle Scholar
• 15  Landau BR, Laszlo J, Stengle J, Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J. Natl Cancer Inst.21,485–494 (1958).
  Medline CASGoogle Scholar
• 16  Atsumi T, Chesney J, Metz C et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res.62,5881–5887 (2002).
  Medline CASGoogle Scholar
• 17  Clem B, Telang S, Clem A et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther.7,110–120 (2008).
  Medline CASGoogle Scholar
• 18  Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol.15,300–308 (2005).
  Medline CASGoogle Scholar
• 19  Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science324,1029–1033 (2009).
  Medline CASGoogle Scholar
• 20  Vander Heiden MG, Christofk HR, Schuman E et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol.79,1118–1124 (2010).
  Medline CASGoogle Scholar
• 21  Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab.3,177–185 (2006).▪▪ Describes the effect of HIF-1 on establishment of tumor metabolic phenotype.
  MedlineGoogle Scholar
• 22  Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively down regulating mitochondrial oxygen consumption. Cell Metab.3,187–197 (2006).
  Medline CASGoogle Scholar
• 23  Whitehouse S, Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem. J.141,761–774 (1974).
  Medline CASGoogle Scholar
• 24  Bonnet S, Archer SL, Allalunis-Turner J et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell11,37–51 (2007).
  Medline CASGoogle Scholar
• 25  Michelakis ED, Sutendra G, Dromparis P et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Trans. Med.2,31ra34 (2010).
  Medline CASGoogle Scholar
• 26  Aicher TD, Damon RE, Koletar J et al. Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK). Bioorg. Med. Chem. Lett.9,2223–2228 (1999).
  Medline CASGoogle Scholar
• 27  Aicher TD, Anderson RC, Gao J et al. Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J. Med. Chem.43,236–249 (2000).
  Medline CASGoogle Scholar
• 28  Bebernitz GR, Aicher TD, Stanton JL et al. Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J. Med. Chem.43,2248–2257 (2000).
  Medline CASGoogle Scholar
• 29  Sonveau P, Vegran F, Schoroeder T et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest.118,3930–3942 (2008).▪▪ First publication showing a controversial hypothesis regarding function of lactic acid production in tumor cells.
  MedlineGoogle Scholar
• 30  Le A, Cooper CR, Gouw AM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA107,2037–2042 (2010).
  Medline CASGoogle Scholar
• 31  Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Cur. Med. Chem.17,672–697 (2010).
  Medline CASGoogle Scholar
• 32  Granchi C, Roy S, De Simone A et al. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. Eur. J. Med. Chem.46,5398–5407 (2011).
  Medline CASGoogle Scholar
• 33  Kroemer G. Mitochondria in cancer. Oncogene25,4630–4632 (2011).▪▪ Detailed review of the functions and significance of mitochondria and mitochondria-based processes in cancer development and progression.
  Google Scholar
• 34  Warburg O. On the origin of cancer cells. Science123,309–314 (1956).
  Medline CASGoogle Scholar
• 35  Vazquez A, Oltvai ZN. Molecular crowding defines a common origin for the Warburg effect in proliferating cells and the lactate threshold in muscle physiology. PLoS ONE6,e19538 (2011).
  Medline CASGoogle Scholar
• 36  Bhalla K, Hwang BJ, Dewi RE et al. PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res.71,6888–6898 (2011).
  Medline CASGoogle Scholar
• 37  D’Errico I, Salvatore L, Murzilli S et al. Peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC1α) is a metabolic regulator of intestinal epithelial cell fate. Proc. Natl Acad. Sci. USA108,6603–6608 (2011).
  MedlineGoogle Scholar
• 38  Wang X, Moraes CT. Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels. Mol. Oncol.5,399–409 (2011).
  Medline CASGoogle Scholar
• 39  Guan KL, Xiong Y. Regulation of intermediary metabolism by protein acetylation. Trends Biochem. Sci.36,108–116 (2011).
  Medline CASGoogle Scholar
• 40  Amoêdo ND, Rodrigues MF, Pezzuto P et al. Energy metabolism in H460 lung cancer cells: effects of histone deacetylase inhibitors. PLoS ONE6,e22264 (2011).
  Medline CASGoogle Scholar
• 41  Hirschey MD, Shimazu T, Jing E et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell44,177–190 (2011).
  Medline CASGoogle Scholar
• 42  Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med. Oncol.29(2),1314–1327 (2011).▪ Detailed consideration of the potential for use of metformin, a widely available hypoglycemic agent, for anticancer treatment.
  MedlineGoogle Scholar
• 43  Biasutto L, Dong LF, Zoratti M, Neuzil J. Mitochondrially targeted anti-cancer agents. Mitochondrion10,670–681 (2010).
  Medline CASGoogle Scholar
• 44  Dong LF, Freeman R, Liu J et al. Suppression of tumor growth in vivo by the mitocan α-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res.15,1593–1600 (2009).
  Medline CASGoogle Scholar
• 45  Raj L, Ide T, Gurkar AU et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature475,231–234 (2011).▪ Interesting example of the effect of a drug leading to an increase in reactive oxygen species level and the initiation of apoptotic cell death in cancer cells.
  Medline CASGoogle Scholar
• 46  Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metfomin in non-insulin-dependent diabetes mellitus. New Eng. J. Med.333,550–554 (1995).
  Medline CASGoogle Scholar
• 47  Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology131,1165–1173 (1992).
  Medline CASGoogle Scholar
• 48  Owen M, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain. Biochem. J.348,607–614 (2000).
  Medline CASGoogle Scholar
• 49  Shaw RJ, Kosmatka M, Bardessey N et al. The tumor supressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA101,3329–3335 (2004).
  Medline CASGoogle Scholar
• 50  Pierotti MA, Berrino F, Gariboldi M et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene doi:10.1038/onc.2012.181 (2012) (Epub ahead of print).
  MedlineGoogle Scholar
• 51  Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Br. Med. J.330,1304–1305 (2005).
  MedlineGoogle Scholar
• 52  Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care29,254–258 (2006).
  MedlineGoogle Scholar
• 53  Blandino G, Valerio M, Cioce M et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat. Commun.3,865 (2012).
  MedlineGoogle Scholar
• 54  Wu B, Li S, Sheng L et al. Metformin inhibits the development and metastasis of ovarian cancer. Oncol. Reprod.28,903–908 (2012).
  Medline CASGoogle Scholar
• 55  Martin M, Marais R. Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? J. Clin. Oncol.30(21),2698–2700 (2012).
  Medline CASGoogle Scholar
• 56  Zaugg K, Yao Y, Reilly PT et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev.25,1041–1051 (2011).
  Medline CASGoogle Scholar
• 57  Zhou W, Tu Y, Simpson PJ, Kuhajda FP. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells. Oncogene28,2979–2987 (2009).
  Medline CASGoogle Scholar
• 58  Nieman KM, Kenny HA, Penicka CV et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med.17,1498–1503 (2011).
  Medline CASGoogle Scholar
• 59  Das SK, Eder S, Schauer S et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science333(6039),233–238 (2011).
  Medline CASGoogle Scholar
• 60  Swinnen JV, Van Veldhoven PP, Timmermans L et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem. Biophys. Res. Commun.302,898–903 (2003).
  Medline CASGoogle Scholar
• 61  Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer7,763–777 (2007).
  Medline CASGoogle Scholar
• 62  Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer100,1369–1372 (2009).
  Medline CASGoogle Scholar
• 63  Migita T, Narita T, Nomura K et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res.68,8547–8554 (2008).
  Medline CASGoogle Scholar
• 64  Hatzivassiliou G, Zhao F, Bauer DE et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell8,311–321 (2005).
  Medline CASGoogle Scholar
• 65  Beckner ME, Fellows-Mayle W, Zhang Z et al. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int. J. Cancer126,2282–2295 (2010).
  Medline CASGoogle Scholar
• 66  Pearce NJ, Yates JW, Berkhout TA et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J.334,113–119 (1998).
  Medline CASGoogle Scholar
• 67  López-Lázaro M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med. Chem.8,305–312 (2008).
  Medline CASGoogle Scholar
• 68  Pappenberger G, Benz J, Gsell B et al. Structure of the human fatty acid synthase KS-MAT didomain as a framework for inhibitor design. J. Mol. Biol.397,508–519 (2010).
  Medline CASGoogle Scholar
• 69  De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res.63,3799–3804 (2003).
  Medline CASGoogle Scholar
• 70  Kridel SJ, Lowther WT, Pemble CW 4th. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Invest. Drugs16,1817–1829 (2007).
  Medline CASGoogle Scholar
• 71  Price AC, Choi KH, Heath RJ, Li Z, White SW, Rock CO. Inhibition of β-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J. Biol. Chem.276,6551–6559 (2001).
  Medline CASGoogle Scholar
• 72  Moche M, Schneider G, Edwards P, Dehesh K, Lindqvist Y. Structure of the complex between the antibiotic cerulenin and its target, β-ketoacyl-acyl carrier protein synthase. J. Biol. Chem.274,6031–6034 (1999).
  Medline CASGoogle Scholar
• 73  Wang X, Tian W. Green tea epigallocatechin gallate: a natural inhibitor of fatty acid synthase. Biochem. Biophys. Res. Commun.288,1200–1206 (2001).
  Medline CASGoogle Scholar
• 74  Menendez JA, Colomer R, Lupu R. Inhibition of fatty acide synthase-dependent neoplastic lipogenesis as the mechanism of γ-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo’s hypothesis. Med. Hypothesis64,337–341 (2005).
  Medline CASGoogle Scholar
• 75  Vázquez MJ, Leavens W, Liu R et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β-ketoacyl reductase reaction. FEBS J.275,1556–1567 (2008).
  Medline CASGoogle Scholar
• 76  Zhan Y, Ginanni N, Tota MR et al. Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin. Cancer Res.14,5735–5742 (2008).
  Medline CASGoogle Scholar
• 77  Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl coA carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res.65,6719–6725 (2005).
  Medline CASGoogle Scholar
• 78  Waldrop GL, Stephens JM. Targeting acetyl coA carboxylase for anti-obesity therapy. Curr. Med. Chem. Immunol. Endocr. Metabol. Agents3,229–234 (2003).
  CASGoogle Scholar
• 79  Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl coA induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun.285,217–223 (2001).
  Medline CASGoogle Scholar
• 80  Wang C, Xu C, Sun M, Luo D, Liao DF, Cao D. Acetyl coA carboxylase-α inhibitor TOFA induces human cancer cell apoptosis. Biochem. Biophys. Res. Commun.385,302–306 (2009).
  Medline CASGoogle Scholar
• 81  Sugimoto Y, Naniwa Y, Nakamura T et al. A novel acetyl-CoA carboxylase inhibitor reduces de novo fatty acid synthesis in HepG2 cells and rat primary hepatocytes. Archiv. Biochem. Biophys.468,44–48 (2007).
  Medline CASGoogle Scholar
• 82  Beckers A, Organe S, Timmermans L et al. Chemical inhibition of acetyl coA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res.67,8180–8187 (2007).
  Medline CASGoogle Scholar
• 83  Harwood HJ Jr, Petras SF, Shelly LD et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J. Biol. Chem.278,37099–37111 (2003).
  Medline CASGoogle Scholar
• 84  Zhang H, Tweel B, Li J, Tong L. Crystal Structure of the carboxyltransferase domain of acetyl-coenzyme a carboxylase in complex with CP-640186. Structure12,1683–1692 (2004).
  Medline CASGoogle Scholar
• 85  Marjanovic J, Chalupska D, Patenode C et al. Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity. Proc. Natl Acad. Sci. USA107,9093–9098 (2010).
  Medline CASGoogle Scholar
• 86  Gu YG, Weitzberg M, Clark RF et al. Synthesis and structure – activity relationships of N-{3-[2-(4-Alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors. J. Med. Chem.49,3770–3773 (2006).
  Medline CASGoogle Scholar
• 87  Vaklavas C, Chatzizisis YS, Tsimberidou AM. Common cardiovascular medications in cancer therapeutics. Pharmcol. Ther.130,177–190 (2011).
  Medline CASGoogle Scholar
• 88  Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf.9,603–621 (2010).
  Medline CASGoogle Scholar
• 89  Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J. Urol.185,1268–1273 (2011).
  Medline CASGoogle Scholar
• 90  Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest131,1282–1288 (2007).
  MedlineGoogle Scholar
• 91  Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk. JAMA295,74–80 (2006).
  Medline CASGoogle Scholar
• 92  Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res.71,1763–1771 (2011).▪ Presentation of the results of statin use in an extremely large, longitudinal cohort of patients.
  Medline CASGoogle Scholar
• 93  Clendening JW, Pandyra A, Boutros PC et al. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl Acad. Sci. USA107,15051–15056 (2010).
  Medline CASGoogle Scholar
• 94  Halestrap AP. The monocarboxylate transporter family-Structure and functional characterization. IUBMB Life64,1–9 (2012).
  Medline CASGoogle Scholar
• 95  Zheng XT, Yang HB, Li CM. Optical detection of single cell lactate release for cancer metabolic analysis. Anal. Chem.82,5082–5087 (2010).
  Medline CASGoogle Scholar
• 96  Semenza GL. Tumor metabolism: cancer cells give and take lactate. J. Clin. Invest.118,3835–3837 (2008).
  Medline CASGoogle Scholar
• 97  Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med.49,S24–S42 (2008).
  Medline CASGoogle Scholar
• 98  Robey IF, Baggett BK, Kirkpatrick D et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res.69,2260–2268 (2009).
  Medline CASGoogle Scholar
• 99  Végran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res.71,2550–2560 (2011).
  Medline CASGoogle Scholar
• 100  Shim CK, Cheon EP, Kang KW, Seo KS, Han HK. Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells. J. Pharm. Pharmacol.59,1515–1519 (2007).
  MedlineGoogle Scholar
• 101  Wang X, Levi AJ, Halestrap AP. Substrate and inhibitor specificities of the monocarboxylate transporters of single rat heart cells. Am. J. Physiol. Heart Circ. Physiol.270,H476–H484 (1996).
  CASGoogle Scholar
• 102  Melena J, Safa R, Graham M, Casson RJ, Osborne NN. The monocarboxylate transport inhibitor, α-cyano-4-hydroxycinnamate, has no effect on retinal ischemia. Brain Res.989,128–134 (2003).
  Medline CASGoogle Scholar
• 103  Murray CM, Hutchinson R, Bantick JR et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat. Chem. Biol.1,371–376 (2005).
  Medline CASGoogle Scholar
• 104  Bueno V, Binet I, Steger U et al. The specific monocarboxylate transporter (MCT1) inhibitor, AR C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation84(9),1204–1207 (2007).
  Medline CASGoogle Scholar
• 105  Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10. Biochem. J.425(3),523–530 (2010).
  Medline CASGoogle Scholar
• 106  Izumi H, Takahashi M, Uramoto H et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci.102,1007–1013 (2011).
  Medline CASGoogle Scholar
• 107  Supuran CT. Carbonic anhydrase inhibitors. Bioorg. Med. Chem. Lett.20,3467–3474 (2010).
  Medline CASGoogle Scholar
• 108  Poulsen S. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007–2009. Expert Opin Ther. Pat.20(6),795–806 (2010).
  Medline CASGoogle Scholar
• 109  Alterio V, Hilvo M, Di Fiore A et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc. Natl Acad. Sci. USA106,16233–16238 (2009).
  Medline CASGoogle Scholar
• 110  Buller F, Steiner M, Frey K et al. Selection of carbonic anhydrase ix inhibitors from one million DNA-encoded compounds. ACS Chem. Biol.6,336–344 (2011).▪▪ Example of a very interesting novel approach for barcoding and testing a large number of chemical compounds for a particular application (in this case inhibition of carbonic anhydrase).
  Medline CASGoogle Scholar
• 111  Pacchiano F, Carta F, McDonald PC et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem.54,1896–1902 (2011).
  Medline CASGoogle Scholar
• 112  Dittrich C, Zandvliet AS, Gneist M, Huitema AD, King AA, Wanders J. A Phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br. J. Cancer96,559–566 (2007).
  Medline CASGoogle Scholar
• 113  Talbot DC, von Pawel J, Cattell E et al. A randomized Phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res.13,1816–1822 (2007).
  Medline CASGoogle Scholar
• 114  Samid D, Yeh A, Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood80,1576–1481 (1992).
  Medline CASGoogle Scholar
• 115  Gao P, Tchernyshyov I, Chang TC et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature458,762–765 (2009).
  Medline CASGoogle Scholar
• 116  Seltzer MJ, Bennett BD, Joshi AD et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res.70,8981–8987 (2010).
  Medline CASGoogle Scholar
• 117  Wang JB, Erickson JW, Fuji R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell18,207–219 (2010).
  Medline CASGoogle Scholar
• 118  Rosenfeld H, Roberts J. Enhancement of antitumour activity of glutamine antagonists 6-diazo-5-oxo-l-norleucine and acivicin in cell culture by glutamineasparginase. Cancer Res.41,1324–1328 (1981).
  Medline CASGoogle Scholar
• 119  Masetti R, Pession A. First-line treatment of acute lymphoblastic leukemia with peg asparaginase. Biologics3,359–368 (2009).
  Medline CASGoogle Scholar
• 120  Haskell CM, Canellos GP. L-asparaginase resistance in human leukemia–asparagine synthetase. Biochem. Pharmacol.18,2578–2580 (1969).
  Medline CASGoogle Scholar
• 121  Haskell CM, Canellos GP, Leventhal BG et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N. Engl. J. Med.281,1028–1034 (1969).
  Medline CASGoogle Scholar
• 122  Wheatley DN. Controlling cancer by restricting arginine availability – arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs15,825–833 (2004).
  Medline CASGoogle Scholar
• 123  Ni Y, Schwaneberg U, Sun ZH. Arginine deiminase, a potential anti-tumor drug. Cancer Lett.261,1–11 (2008).
  Medline CASGoogle Scholar
• 124  Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res.32(Database issue),D277–D280 (2004).
  Medline CASGoogle Scholar
• 201  THE JOHN HOPKINS UNIVERSITY: WO2008076964 (2008).
  Google Scholar
• 202  THE JOHN HOPKINS UNIVERSITY: WO2006042062 (2006).
  Google Scholar
• 203  Lakatos GC: US4620972 (1986).
  Google Scholar
• 204  UNIVERSITÀ DI PISA: WO2011054525 (2011).
  Google Scholar
• 301  SciFinder^®. www.cas.org/products/scifinder
  Google Scholar
• 302  Cancer Research UK Press Release (2010). www.cancerresearchuk.org/cancer-info/news/archive/pressrelease/2010-09-13-%20cancer-drug-astrazeneca
  Google Scholar
• 303  NIH. ClinicalTrials.gov. www.clinicaltrials.gov
  Google Scholar